Barrington Research Maintains Outperform on HealthEquity, Maintains $105 Price Target
Portfolio Pulse from Benzinga Newsdesk
Barrington Research analyst Alexander Paris has reiterated an 'Outperform' rating for HealthEquity (NASDAQ:HQY) and maintained a price target of $105.
September 05, 2024 | 12:28 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barrington Research has reaffirmed its 'Outperform' rating for HealthEquity, maintaining a price target of $105. This suggests confidence in the company's future performance.
The reaffirmation of an 'Outperform' rating and a maintained price target of $105 by Barrington Research indicates a positive outlook on HealthEquity's stock. This could lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100